Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Odronextamab - Regeneron Pharmaceuticals

X
Drug Profile

Odronextamab - Regeneron Pharmaceuticals

Alternative Names: CD20xCD3 bispecific antibody - Regeneron Pharmaceuticals; Ordspono; REGN-1979; ZL-1307

Latest Information Update: 29 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Diffuse large B cell lymphoma; Follicular lymphoma
  • Phase III Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Phase I B-cell lymphoma; Chronic lymphocytic leukaemia

Most Recent Events

  • 14 Jan 2025 University of Washington in collaboration with Regeneron Pharmaceuticals plan a phase II trial for Diffuse large B cell lymphoma (Second-line therapy or greater, Recurrent) in USA (IV) in April 2025 (NCT06784726)
  • 09 Dec 2024 Regeneron Pharmaceuticals announces intention to file US FDA regulatory resubmission for odronextamab in Follicular lymphoma after two or more lines of systemic therapy in the first half of 2025.
  • 09 Dec 2024 Efficacy and adverse event data from the phase III OLYMPIA-1 trial in Follicular lymphoma released by Regeneron Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top